Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jacobsson

Showing results (321-330 of 325) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 325 results.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Arthritis Care & Research|November 30, 2020
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment CoursesBente Glintborg, Ulf Lindström, Daniela Di Giuseppe, et al.
Annals of the Rheumatic Diseases|September 11, 2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of goutDavid Bursill, William J Taylor, Robert Terkeltaub, et al.
Nature Genetics|October 15, 2024
A genome-wide association analysis reveals new pathogenic pathways in goutTanya J Major, Riku Takei, Hirotaka Matsuo, et al.
Nature Genetics|November 5, 2024
Publisher Correction: A genome-wide association analysis reveals new pathogenic pathways in goutTanya J Major, Riku Takei, Hirotaka Matsuo, et al.
Pageof 33

Showing results (321-330 of 325) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 325 results.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Arthritis Care & Research|November 30, 2020
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment CoursesBente Glintborg, Ulf Lindström, Daniela Di Giuseppe, et al.
Annals of the Rheumatic Diseases|September 11, 2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of goutDavid Bursill, William J Taylor, Robert Terkeltaub, et al.
Nature Genetics|October 15, 2024
A genome-wide association analysis reveals new pathogenic pathways in goutTanya J Major, Riku Takei, Hirotaka Matsuo, et al.
Nature Genetics|November 5, 2024
Publisher Correction: A genome-wide association analysis reveals new pathogenic pathways in goutTanya J Major, Riku Takei, Hirotaka Matsuo, et al.
Pageof 33